Invex Therapeutics Stock Current Ratio
| IXC Stock | 0.07 0.01 7.46% |
Invex Therapeutics fundamentals help investors to digest information that contributes to Invex Therapeutics' financial success or failures. It also enables traders to predict the movement of Invex Stock. The fundamental analysis module provides a way to measure Invex Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Invex Therapeutics stock.
Invex | Current Ratio |
Invex Therapeutics Company Current Ratio Analysis
Invex Therapeutics' Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.
Typically, short-term creditors will prefer a high current ratio because it reduces their overall risk. However, investors may prefer a lower current ratio since they are more concerned about growing the business using assets of the company. Acceptable current ratios may vary from one sector to another, but the generally accepted benchmark is to have current assets at least as twice as current liabilities (i.e., Current Ration of 2 to 1).
| Competition |
In accordance with the recently published financial statements, Invex Therapeutics has a Current Ratio of 0.0 times. This indicator is about the same for the Biotechnology average (which is currently at 0.0) sector and about the same as Health Care (which currently averages 0.0) industry. This indicator is about the same for all Australia stocks average (which is currently at 0.0).
Did you try this?
Run Idea Analyzer Now
Idea AnalyzerAnalyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas |
| All Next | Launch Module |
Invex Fundamentals
| Return On Equity | -0.12 | ||||
| Return On Asset | -0.0922 | ||||
| Profit Margin | (1.35) % | ||||
| Operating Margin | 0.29 % | ||||
| Current Valuation | (613.99 K) | ||||
| Shares Outstanding | 75.15 M | ||||
| Shares Owned By Insiders | 67.72 % | ||||
| Price To Book | 0.95 X | ||||
| Price To Sales | 4.46 X | ||||
| Revenue | 1.21 M | ||||
| Gross Profit | 459.08 K | ||||
| EBITDA | (720.44 K) | ||||
| Net Income | (1.64 M) | ||||
| Total Debt | 431.63 K | ||||
| Book Value Per Share | 0.08 X | ||||
| Cash Flow From Operations | (2.44 M) | ||||
| Earnings Per Share | (0.02) X | ||||
| Beta | 0.41 | ||||
| Market Capitalization | 5.41 M | ||||
| Total Asset | 6.12 M | ||||
| Retained Earnings | (19.22 M) | ||||
| Working Capital | 5.69 M | ||||
| Net Asset | 6.12 M |
About Invex Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Invex Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Invex Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Invex Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Invex Stock Analysis
When running Invex Therapeutics' price analysis, check to measure Invex Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Invex Therapeutics is operating at the current time. Most of Invex Therapeutics' value examination focuses on studying past and present price action to predict the probability of Invex Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Invex Therapeutics' price. Additionally, you may evaluate how the addition of Invex Therapeutics to your portfolios can decrease your overall portfolio volatility.